Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

24.96 +0.42 (+1.71%)

Streaming Delayed Price Updated: 1:05 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Where Edgewise Therapeutics Stands With Analysts ↗

August 16, 2023

Via Benzinga

Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 10, 2023

From Edgewise Therapeutics

Via Business Wire

Analyst Ratings for Edgewise Therapeutics ↗

June 27, 2023

Via Benzinga

CIRCOR International, Enovix, Edgewise Therapeutics And Other Big Stocks Moving Higher On Tuesday ↗

June 27, 2023

U.S. stocks traded higher, with the Dow Joned gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Edgewise Therapeutics: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 27, 2023

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.

Via Benzinga

Edgewise Therapeutics Touts Positive Data From Investigational Drug In Form Of Muscular Dystrophy ↗

June 27, 2023

Edgewise Therapeutics Inc (NASDAQ: EWTX) released 12-month topline results from the ARCH study, an open-label, single-center study assessing EDG-5506 in adults with

Via Benzinga

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

June 26, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference

June 06, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 11, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

May 02, 2023

From Edgewise Therapeutics

Via Business Wire

Flexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise Therapeutics ↗

May 01, 2023

Truist initiated coverage on Edgewise Therapeutics Inc (NASDAQ: EWTX) with a Buy rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday ↗

April 25, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)

March 30, 2023

From Edgewise Therapeutics

Via Business Wire

Top 5 Health Care Stocks That Preparing To Pump This Quarter ↗

March 29, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023

March 21, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference

March 14, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

March 06, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023

March 01, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology

February 28, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

February 23, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023

February 07, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

January 04, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023

December 21, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

December 20, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

November 09, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Third Quarter 2022 Financial Results

November 03, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

October 27, 2022

From Edgewise Therapeutics

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.